In the wake of the increase in Current Liabilities in the third quarter 2025, Quick Ratio fell to 0.01 a new company low.

Within Biotechnology & Pharmaceuticals industry 155 other companies have achieved higher Quick Ratio than Windtree Therapeutics Inc in third quarter 2025. While Quick Ratio total ranking in the third quarter 2025 has deteriorated compared to the prior quarter from 2984 to 5160.

Explain Quick Ratio?
How much Cash & cash equivalents WINT�s has?
What are WINT�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/WINT/financial-strength

https://api.csimarket.com/api/v1/companies/WINT/fundamentals

https://api.csimarket.com/api/v1/companies/WINT/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

WINT Quick Ratio	(Sep 30 2025) Q3	(Jun 30 2025) Q2	(Mar 31 2025) Q1	(Dec 31 2024) Q4	(Sep 30 2024) Q3
Y / Y Current Liabilities Change	51.82 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-91.13 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.01	Subscribe	Subscribe	Subscribe	Subscribe
WINT's Total Ranking	# 5160	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	39.31 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-88.01 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2025 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 156
Healthcare Sector	# 1028
Overall Market	# 5160

Quick Ratio Statistics
High	Average	Low
7.28	2.33	0.01
(Dec 31 2013)		(Sep 30 2025)

Financial Statements
Windtree Therapeutics Inc's Current Liabilities	$ 22 Millions	Visit WINT's Balance sheet
Windtree Therapeutics Inc's Cash & cash equivalent	$ 0 Millions	Visit WINT's Balance sheet
Source of WINT's Sales		Visit WINT's Sales by Geography

Cumulative Windtree Therapeutics Inc's Quick Ratio

WINT's Quick Ratio for the trailling 12 Months

WINT Quick Ratio	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months	(Mar 31 2025) 12 Months	(Dec 31 2024) 12 Months	(Sep 30 2024) 12 Months
Y / Y Current Liabilities TTM Growth	59.15 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-55.72 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	0.1	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3421	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	17.65 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-30.15 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to WINT Financial Strength Comparisons >> Go to Compare WINT Quick Ratio to its Competitors

News about Windtree Therapeutics Inc Quick Ratio

Windtree Therapeutics Completes $129 Million Transaction with New Funding and Full Cancellation of Outstanding Senior Notes

Windtree Therapeutics Completes $12.9 Million Transaction with New Funding and Full Cancellation of Outstanding Senior Notes
Windtree Therapeutics has recently announced the successful completion of a $12.9 million transaction, which includes approximately $3.4 million of new funding and a $9.5 million full cancellation of outstanding senior notes. This transaction also marks the extinguishment of Series B Preferred Shares, further solidifying the company s financial position and strategic direction.
The infusion of new funding will enable Windtree Therapeutics to accelerate its research and development efforts, as well as expand its pipeline of innovative therapeutic solutions. The full cancellation of outstanding senior notes demonstrates the company s commitment to strengthening its balance sheet and reducing its debt obligations.

On the trailing twelve months basis Due to growth in Current Liabilities in the Q3 2025 to $21.90 millions, cumulative Quick Ratio decreased to 0.1 below the average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 147 other companies have achieved higher Quick Ratio than Windtree Therapeutics Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2025 from 3034 to 3421.

Explain Quick Ratio?
How much Cash & cash equivalents WINT�s has?
What are WINT�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 148
Healthcare Sector	# 906
Within the Market	# 3421

trailing twelve months Quick Ratio Statistics
High	Average	Low
6.14	2.23	0.08
(Dec. 30, 2014)		(Sep 30 2018)

Companies with similar Quick Ratio in the quarter ending Sep 30 2025, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Sep 30 2025 MRQ Cash & cash equivalent	Sep 30 2025 MRQ Current Liabilities
Atlantic Coastal Acquisition Corp Ii	0.02	$ 0.394 Millions	$ 17.298 Millions
Agenus Inc	0.01	$ 3.458 Millions	$ 287.132 Millions
Windtree Therapeutics Inc	0.01	$ 0.204 Millions	$ 21.901 Millions
Mosaic Immunoengineering Inc	0.01	$ 0.032 Millions	$ 5.915 Millions
Black Hawk Acquisition Corporation	0.01	$ 0.015 Millions	$ 2.961 Millions
Scilex Holding Company	0.00	$ 0.878 Millions	$ 358.948 Millions
Zivo Bioscience Inc	0.00	$ 0.008 Millions	$ 3.614 Millions

Date modified: 2026-10-05T11:03:38+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.